RECHERCHEDosage des marqueurs tumoraux CYFRA 21-1 et ACEdans le cancer du nasopharynx en Algérie

dc.contributor.authorBENDJEMANA KATIA
dc.date.accessioned2024-02-27T10:05:48Z
dc.date.available2024-02-27T10:05:48Z
dc.date.issued2013-03-09
dc.description.abstractNasopharyngeal cancer is one of the most important cancers in our country. It ischaracterized by the influence of different etiologic factors: viral, genetic and environmental.Its diagnosis is delayed by lack of specific tumor markers. The aim of this study was to evaluatethe importance of the use of CYFRA 21-1 and ACE markers in nasopharyngeal carcinoma (NPC).Our prospective study interested 164 patients (132 M, 32 F) with a mean age of 47 years (13 to 70)with 24 of them aged less than 30 years, presenting a nasopharyngeal carcinoma histologicallyconfirmed and 180 healthy controls without evident neoplasm. Undifferentiated forms represent93% of cases. A blood sample was collected from each patient and control before any treatment,as well as controls to measure CYFRA 21-1 and ACE by immunoenzymatic assay. The resultsshowed that the mean serum CYFRA 21-1 values were significantly higher in patients with NPCthan those in controls (P ± 0.001). A significant correlation was found only between the serumCYFRA 21-1 level before treatment and the clinical outcome of patients (P ± 0.0009). Seric levelof CYFRA 21-1 at diagnosis of NPC may play a predictive role to evaluate the risk of metastaticdisease and prognosis.
dc.identifier.urihttp://dspace.univ-khenchela.dz:4000/handle/123456789/2130
dc.language.isofr
dc.publisherelsevier
dc.titleRECHERCHEDosage des marqueurs tumoraux CYFRA 21-1 et ACEdans le cancer du nasopharynx en Algérie
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Dosage des marqueurs tumoraux CYFRA 21-1 et ACE dans le cancer du nasopharynx en Algérie.pdf
Size:
408.7 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: